Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guérin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice

Clinical and Vaccine Immunology

Volumn 19, Issue 12, 2012, Pages 1932-1937

  Fujii, Jun ^a   Naito, Mariko ^b   Yutsudo, Takashi ^c   Matsumoto, Sohkichi ^d   Heatherly, Daniel P ^e   Yamada, Takeshi ^b   Kobayashi, Hideyuki ^f   Yoshida, Shin Ichi ^a   Obrig, Tom ^g  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT BCG VACCINE EXPRESSING SHIGA TOXIN 2B SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE FLORA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI INFECTION;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; FEMALE; GENETIC VECTORS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; SHIGA TOXIN 2; SHIGA-TOXIGENIC ESCHERICHIA COLI; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 84870419899     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00473-12     Document Type: Article

References (37)

1. Acheson DW, Levine MM, Kaper JB, Keusch GT. 1996. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:355-357.
2. Bosworth BT, et al. 1996. Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine. Infect. Immun. 64:55- 60.
3. Cohen A, et al. 1990. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int. Immunol. 2:1- 8.
4. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. U. S. A. 90:11473-11477. (Pubitemid 24008661)
5. Endo Y, et al. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:45-50. (Pubitemid 18042873)
6. Fernandez-Brando RJ, et al. 2011. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS One 6:e19136. doi:10.1371/journal.pone. 0019136.
7. Frank C, et al. 2011. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365:1771-1780.
8. Friedrich AW, et al. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84. (Pubitemid 34043019)
9. Gheorghiu M, Lagrange PH, Fillastre C. 1988. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J. Biol. Stand. 16:15-26.
10. Hayward CM, et al. 1999. Construction and murine immunogenicity of recombinant Bacille Calmette Guerin vaccines expressing the B subunit of Escherichia coli heat labile enterotoxin. Vaccine 17:1272-1281. (Pubitemid 29132962)
11. Imai Y, et al. 2005. Production of IgA monoclonal antibody against Shiga toxin binding subunits employing nasal-associated lymphoid tissue. J. Immunol. Methods 302:125-135. (Pubitemid 41111879)
12. Karmali MA, Steele BT, Petric M, Lim C. 1983. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet i:619-620. (Pubitemid 13152343)
13. Kawahara M, Hashimoto A, Toida I, Honda M. 2002. Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin. Immunol. 105:326-331. (Pubitemid 36016060)
14. Kokai-Kun JF, Melton-Celsa AR, O'Brien AD. 2000. Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d. J. Biol. Chem. 275:3713-3721. (Pubitemid 30083085)
15. Langermann S, Palaszynski S, Sadziene A, Stover CK, Koenig S. 1994. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372:552-555. (Pubitemid 24368537)
16. Langermann S, et al. 1994. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 180:2277-2286.
17. Lindgren SW, Melton AR, O'Brien AD. 1993. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect. Immun. 61:3832-3842. (Pubitemid 23260057)
18. Lingwood CA, et al. 1987. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 262:8834-8839.
19. Ludwig K, Karmali MA, Smith CR, Petric M. 2002. Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid. Can. J. Microbiol. 48:99-103. (Pubitemid 34258655)
20. Mangeney M, et al. 1993. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 53:5314-5319. (Pubitemid 23333405)
21. Matano S, et al. 2012. Encephalopathy, disseminated intravascular coagulation, and hemolytic-uremic syndrome after infection with enterohemorrhagic Escherichia coli O111. J. Infect. Chemother. 18:558-564.
22. Matsumoto S, et al. 1996. A stable Escherichia coli-mycobacteria shuttle vector 'pSO246' in Mycobacterium bovis BCG. FEMS Microbiol. Lett. 135:237-243. (Pubitemid 26048884)
23. Matsumoto S, Yukitake H, Kanbara H, Yamada T. 1998. Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J. Exp. Med. 188:845-854. (Pubitemid 28433411)
24. Matsuo K, Yamaguchi R, Yamazaki A, Tasaka H, Yamada T. 1988. Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen. J. Bacteriol. 170:3847-3854.
25. Michino H, et al. 1999. Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am. J. Epidemiol. 150:787-796. (Pubitemid 29482831)
26. Muthing J, Schweppe CH, Karch H, Friedrich AW. 2009. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb. Haemost. 101:252-264.
27. Myhal ML, Laux DC, Cohen PS. 1982. Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice. Eur. J. Clin. Microbiol. 1:186-192. (Pubitemid 12061075)
28. Naito M, Ohara N, Matsumoto S, Yamada T. 1998. Immunological characterization of alpha antigen of Mycobacterium kansasii: B-cell epitope mapping. Scand. J. Immunol. 48:73-78. (Pubitemid 28329155)
29. O'Brien AD, Holmes RK. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206-220. (Pubitemid 17082511)
30. Obrig TG, Moran TP, Brown JE. 1987. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem. J. 244:287-294. (Pubitemid 17087091)
31. Ohara N, Yamada T. 2001. Recombinant BCG vaccines. Vaccine 19:4089-4098. (Pubitemid 32703627)
32. Pierard D, Muyldermans G, Moriau L, Stevens D, Lauwers S. 1998. Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J. Clin. Microbiol. 36:3317-3322. (Pubitemid 28476185)
33. Riley LW, et al. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl.J. Med. 308:681-685. (Pubitemid 13157770)
34. Taga S, et al. 1997. Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood 90:2757-2767. (Pubitemid 27413486)
35. Tsuji T, et al. 2008. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 26:2092-2099.
36. Yasuhara A, Araki A, Ochi A, Kobayashi Y. 2000. Magnetic resonance imaging of brain lesions of a patient with hemolytic uremic syndrome following Escherichia coli O157 infection. Pediatr. Int. 42:302-305. (Pubitemid 30409348)
37. Yutsudo T, Nakabayashi N, Hirayama T, Takeda Y. 1987. Purification and some properties of a Vero toxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin. Microb. Pathog. 3:21-30.